monoclonal antibody tagged posts

The SARS-CoV-2 virus that causes COVID-19 has killed 6 million people worldwide since 2019.

Researchers now have discovered a monoclonal antibody that potentially acts as a potent universal coronavirus therapy against the COVID-19 virus and all its variants of concern, including delta and omicron. It also shows effectiveness against the deadly coronaviruses SARS, the Severe Acute Respiratory Syndrome that emerged in China in 2002, and MERS, the Middle East Respiratory Syndrome that appeared in Saudi Arabia in 2012. It even shows effectiveness against several common cold coronaviruses.

This universal activity results from the monoclonal antibody targeting a region of the viral spike protein that is highly conserved among beta-coronaviruses, yet i...

Plasma cells at the center of a novel treatment approach. Researchers from Charité — Universitätsmedizin Berlin and the Deutsches Rheuma-Forschungszentrum (DRFZ) Berlin, a Leibniz Institute, have successfully treated two patients with the autoimmune disease systemic lupus erythematosus. Using daratumumab, a monoclonal antibody which targets specific immune cells known as plasma cells, the researchers were able to modulate the abnormal immunological memory processes found in these patients. Treatment induced sustainable clinical responses and resulted in a reduction in systemic inflammation. The results of this research have been published in the New England Journal of Medicine.

The body’s immunological memory enables the immune system to respond more rapidly and effectively to pa...

Romosozumab is a monoclonal antibody that binds and inhibits sclerostin. This increases bone formation and decreases bone resorption

Romosozumab associated with rapid and large reductions in risk of vertebral fracture compared to placebo. The results of a study presented at the Annual European Congress of Rheumatology (EULAR) 2017 press conference showed that, in postmenopausal women with osteoporosis, 12 months treatment with romosozumab was associated with rapid and large reductions in their risk of a vertebral fracture compared to placebo.

In those women receiving romosozumab, all clinical vertebral fractures occurred in the first 2 months of treatment; overall, the risk of a vertebral fracture was more than 5 times greater in the group of women given placebo...